Your shopping cart is currently empty

INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression, and exhibits anticancer activity in ccne1-amplified cancers and cdk4/6i-resistant intraductal breast cancer models.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $67 | - | In Stock | |
| 5 mg | $162 | - | In Stock | |
| 10 mg | $293 | In Stock | In Stock | |
| 25 mg | $397 | - | In Stock | |
| 50 mg | Preferential | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $198 | - | In Stock |
| Description | INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression, and exhibits anticancer activity in ccne1-amplified cancers and cdk4/6i-resistant intraductal breast cancer models. |
| In vitro | INX-315 (30-300 nM, 24 hours) treatment of OVCAR3 and MKN1 cells effectively inhibited cell cycle progression by downregulating the phosphorylation of retinoblastoma protein (Rb) [1]. INX-315 (0.3 nM - 10 μM, 6 days) treatment of CCNE1-amplified ovarian cancer cell lines significantly suppressed cell proliferation [1]. |
| In vivo | In the BALB/c nude mouse model of gastric adenocarcinoma, oral administration of INX-315 at a dose of 100 mg/kg (twice daily for 56 consecutive days) effectively inhibited tumor growth [1]. In the OVCAR3 ovarian cancer Parazacco spilurus subsp. In a Spilurus xenograft model, intraperitoneal injection of INX-315 at doses of 100 mg/kg (twice daily) or 200 mg/kg (once daily) for 42 days demonstrated significant tumor suppression and was well tolerated [2]. In the GA0103 gastric cancer Parazacco spilurus subsp. spilurus xenograft model, intraperitoneal injection of INX-315 at a dose of 100 mg/kg (twice daily for 56 consecutive days) exhibited notable antitumor activity with favorable tolerability [2]. |
| Molecular Weight | 427.48 |
| Formula | C19H21N7O3S |
| Cas No. | 2745060-92-6 |
| Smiles | O=C1NNC2=CC=3C=NC(=NC3N2C14CCCCC4)NC5=CC=C(C=C5)S(=O)(=O)N |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (187.14 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.